Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Takeda_family
|
| gptkbp:acquisition |
gptkb:Zymeworks
gptkb:Archer_DX gptkb:Ti_Genix gptkb:Apexigen gptkb:Tigenix gptkb:Envoy_Therapeutics gptkb:Shire_plc gptkb:Hikma_Pharmaceuticals gptkb:mountain gptkb:Nant_Kwest Ligo Cyte Pharmaceuticals |
| gptkbp:ceo |
gptkb:Christophe_Weber
|
| gptkbp:employees |
50,000+
|
| gptkbp:founded |
1781
|
| gptkbp:founder |
gptkb:Chobei_Takeda_I
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Takeda Pharmaceuticals
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:partnership |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
gptkb:temple gptkb:Novavax gptkb:Nant_Kwest |
| gptkbp:products |
medications
|
| gptkbp:research_focus |
oncology
rare diseases neuroscience gastroenterology |
| gptkbp:revenue |
$30 billion (2021)
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Takeda_Pharmaceuticals_USA,_Inc.
|
| gptkbp:symbol |
4502
|
| gptkbp:website |
www.takeda.com
|